DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Portage Biotech in Tarus Therapeutics Acquisition
July 19, 2022
Read time: 3 min
International law firm McDermott Will and Emery represented Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, in its agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists.
Portage acquired Tarus in exchange for 2,425,999 shares of Portage along with the assumption of $3 million of Tarus’ liabilities. Portage will gain four best-in-class assets targeting different aspects of the adenosine pathway as part of the acquisition.
The McDermott team advising Portage is led by Bob Cohen and Eric Klee and includes Alex Laznovsky, Jeronimo Soares de Sousa, Myia Williams, Dan Zucker, Michael Siekman, Brian Malkin, Anisa Mohanty, Michelle Strowhiro and Daphne Trotter.
For more details, read Portage Biotech’s full press release here.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Represents Multicoin Capital in Formation of $430 Million Venture Fund III
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Multicoin Capital in Formation of $430 Million Venture Fund III
July 19, 2022
Read time: 3 min
International law firm McDermott Will & Emery represented Multicoin Capital, a thesis-driven investment firm that invests in cryptocurrencies, tokens and blockchain companies, in the formation of Venture Fund III, which closed with capital commitments of $430 million. The fund will provide capital for early- and later-stage projects focused on data-aggregating decentralized autonomous organizations, open finance, Web3 infrastructure and consumer social opportunities, among other initiatives.
The McDermott team was led by David Solander and included Rafael Calatrava, John Lutz, Andrew Granek and Todd Solomon.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
SRZ Files Supreme Court Amicus Brief in Alabama Voting Rights Act Case
PRESS RELEASE
SRZ Files Supreme Court Amicus Brief in Alabama Voting Rights Act Case
July 2022
Read time: 3 min
On behalf of the Southern Poverty Law Center (SPLC), the League of Women Voters of Alabama (LWVAL), the League of Women Voters of the United States (LWVUS) and Stand-Up Mobile, a pro bono team from SRZ has filed an amicus brief with the U.S. Supreme Court in Merrill v. Milligan that:
(1) Explains the current ties and deep history connecting the City of Mobile to Alabama’s Black Belt to demonstrate that they form a community of interest and may be properly joined in a new redistricting map that would create a second majority-Black congressional district in Alabama, and
(2) Argues that state legislatures do not violate the Equal Protection clause simply by considering race-correlated factors in identifying the “communities of interest” who can together constitute an effective voting district.
Attorneys and staff from all of SRZ’s offices in New York, Washington D.C., and London participated in this effort. The pro bono team included Gary Stein, Alexandra (Alex) Carlton, Noah Gillespie, Savannah Price, Lauren Bidwell, Ashley Bogdan, Alex Mason-Pazmiño, Brennan McCray, Crystal Mor Henwood, Noah Wright and Donna Angiulo.
Read the SPLC press release here.
Media Contact
McDermott Represents Pasithea Therapeutics in Alpha-5 Integrin, LLC Acquisition
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Pasithea Therapeutics in Alpha-5 Integrin, LLC Acquisition
July 13, 2022
Read time: 3 min
International law firm McDermott Will & Emery represented Pasithea Therapeutics Corp. (Pasithea), a US biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, in its acquisition of Alpha-5 Integrin, LLC (Alpha-5), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis and other neuroinflammatory disorders, such as multiple sclerosis.
Pasithea acquired all of Alpha-5’s issued and outstanding equity interests in exchange for 3,260,870 shares of Pasithea common stock plus warrants to acquire an additional 1,000,000 shares. The acquisition includes potential future earnouts based on net sales.
The McDermott team was led by Bob Cohen and Eric Klee and included Graciany Miranda, Jeronimo Soares de Sousa, Dan Zucker, Michael Siekman, Rodney Swartz, Todd Solomon, Evan Belosa, Nick Paul, David Saunders, Michelle Stowhiro, Abigail Kagan, Richard Bass and Brandon Sloane.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Advises Five Arrows Principal Investments on the Sale of Pharmacie Lafayette to Latour Capital
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Advises Five Arrows Principal Investments on the Sale of Pharmacie Lafayette to Latour Capital
July 13, 2022
Read time: 3 min
McDermott Will & Emery advised Five Arrows Principal Investments on the sale of Pharmacie Lafayette, a multi-brand group dedicated to health, to Latour Capital.
Five Arrows Principal Investments acquired a stake in Pharmacie Lafayette in 2016. Pharmacie Lafayette has now nearly 250 members with a target of 300 by the end of the year.
The McDermott team that advised Five Arrows Principal Investments included:
· Grégoire Andrieux, managing partner, Herschel Guez, counsel & Claire Barra, associate, on the corporate aspects;
· Pierre-Arnoux Mayoly, partner, & Aurélien Jugand, counsel, on the financing aspects;
· Antoine Vergnat, partner, Romain Desmonts, counsel & Paul-Henry de Laguiche, associate on the tax aspects;
· Anne-France Moreau, partner, Caroline Noyrez & Camille Michaud, associates, on the life sciences aspects;
· Frédéric Pradelles, partner, on antitrust aspects.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Represents Quote.com in Acquisition of Ring2Media Inc.
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Quote.com in Acquisition of Ring2Media Inc.
July 12, 2022
Read time: 3 min
International law firm McDermott Will & Emery represented Quote.com, a portfolio company of Osceola Capital, in its acquisition of Ring2Media Inc., a direct response marketing agency specializing in Medicare enrollment. The acquisition will be consolidated under the Quote.com brand and accelerate the company’s highly strategic Medicare segment.
- The Ring2Media acquisition further diversifies Quote.com’s core digital product offering by adding expertise in TV/OTT marketing, expanding the company’s reach and addressable audience.
- Read the press release.
- The McDermott team was led by Brian Gordon, Sarah Sarb, Greg Weigand, Brian Tiemann, Nick Paul, Michelle Strowhiro, Cristell Fortune, Abigail Kagan, David Saunders, Jennifer Mikulina, Tom DaMario, Jared Bryant, Caitlin Harrington, John Parker and Robin Riley.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Represents Wentworth Management Services LLC in its Business Combination with Kingswood Acquisition Corp.
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Wentworth Management Services LLC in its Business Combination with Kingswood Acquisition Corp.
July 8, 2022
Read time: 3 min
International law firm McDermott Will & Emery represented Wentworth Management Services LLC (Wentworth), a holding company that acquires and manages businesses in the wealth management industry, in a business combination agreement with Kingswood Acquisition Corp. (KWAC), a blank check company. The merger will create Binah Capital Group, Inc., where Wentworth and KWAC will become wholly owned subsidiaries.
- The transaction was announced July 7, 2022, and is expected to close in the fourth quarter of 2022, subject to customary closing requirements.
- This deal allows Wentworth to go public, giving them access to public equity markets.
- The combined entity is expected to encompass over 1,900 advisors, $25 billion in assets under management and over $285 billion in affiliated assets under management. The combined company will have a pro forma enterprise value of $208 million.
- The McDermott team was led by Griffin Doty and Ari Edelman and included Rodrigo Castello Branco, Anand Saha, Caroline Sandy and Tipanun Bisalbutr. Jerry Sokol is the relationship partner for Wentworth.
- Read the press release.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
SRZ Represents Four Members of Republic First Bancorp Board of Directors
PRESS RELEASE
Blank Media template
Read time: 2 min
Media Contact
McDermott advised Advicenne on its distribution agreement with Taïba Healthcare for the commercialization of Sibnayal® in selected Middle East countries
PRESS RELEASE
McDermott advised Advicenne on its distribution agreement with Taïba Healthcare for the commercialization of Sibnayal® in selected Middle East countries
July 7, 2022
Read time: 2 min
Paris, July 7, 2022 – McDermott Will & Emery advised Advicenne, a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, on its exclusive distribution agreement with Taïba Healthcare, a pharmaceutical company based in the Sultanate of Oman, for the commercialization of Sibnayal® in selected Middle East countries.
The McDermott team that advised Advicenne comprised:
- Emmanuelle Trombe, partner and Edouard Becker, associate.
Media Contact
McDermott Advises Ryvu Therapeutics on Exclusive License Agreement with Exelixis
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Advises Ryvu Therapeutics on Exclusive License Agreement with Exelixis
July 7, 2022
Read time: 3 min
Frankfurt, July 7, 2022 – McDermott Will & Emery advised Ryvu Therapeutics S.A. on entering into an exclusive license agreement with Exelixis. The cooperation is focused on the development of novel targeted therapies utilizing Ryvu’s STING (STimulator of INterferon Genes) technology.
Under the terms of the agreement, Exelixis will pay Ryvu an upfront fee of $3 million in exchange for certain rights to Ryvu’s STING agonist small molecules, which Exelixis will seek to incorporate into targeted therapies such as ADCs. Ryvu will provide expert guidance and know-how during the early research phase of the partnership, and will be eligible to receive development, regulatory and commercialization milestone payments, as well as tiered royalties on the annual net sales of any products that are successfully commercialized under the collaboration.
Ryvu Therapeutics S.A. is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. The company headquartered in Krakow, Poland, is listed on the Warsaw Stock Exchange.
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.
Ryvu Therapeutics S.A. was advised by Frankfurt Counsel Monika Emilia Richter.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
